HAYWARD, Calif.–(Business enterprise WIRE)–Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-centered biopharmaceutical organization functioning to produce finest-in-class cancer therapies, now announced that the Payment Committee of the Company’s Board of Directors granted 10 new workers alternatives to purchase a whole of 141,800 shares of the Company’s prevalent inventory at an exercising rate per share of $23.40, which was the closing rate on June 23, 2021. The stock solutions were being granted pursuant to the Company’s 2020 Inducement Approach, which was authorized by the Company’s Board of Administrators in January 2020 pursuant to the “inducement exception” less than NYSE Outlined Business Manual Rule 303A.08.
About Arcus Biosciences
Arcus Biosciences is an oncology-focused biopharmaceutical company leveraging its deep cross-disciplinary expertise to discover highly differentiated therapies and to build a wide portfolio of novel combos addressing important unmet needs. Arcus at the moment has 5 molecules in medical enhancement: Etrumadenant (AB928), the first twin A2a/A2b adenosine receptor antagonist to enter the clinic, is currently being evaluated in many Phase 2 and 1b scientific tests across unique indications, together with prostate, colorectal, non-smaller cell lung, and pancreatic cancers. AB680, the initially small-molecule CD73 inhibitor to enter the clinic, is in Section 1/1b enhancement in blend with zimberelimab and gemcitabine/nab-paclitaxel for 1st-line treatment of metastatic pancreatic most cancers. Domvanalimab (AB154) is an Fc-silent anti-TIGIT monoclonal antibody and new opportunity immuno-oncology backbone remedy. In addition to ARC-7, domvanalimab is getting investigated in a registrational, Stage 3 analyze, ARC-10, a “two in 1 trial” to aid the probable approvals of both zimberelimab on your own and domvanalimab in addition zimberelimab compared to chemotherapy in 1st-line regionally innovative or metastatic, PD-L1>50% NSCLC. An extra registrational Stage 3 research is currently being planned in collaboration with AstraZeneca in previously sickness with healing intent. AB308, an anti-TIGIT antibody that is Fc-enabled, is in medical development, with a opportunity aim on hematological malignancies. Zimberelimab (AB122), Arcus’s anti-PD-1 monoclonal antibody, is getting evaluated in several combos throughout the portfolio. For more information and facts about Arcus Biosciences, please take a look at www.arcusbio.com or comply with us on Twitter.
Source: Arcus Biosciences